Innate Pharma to host key opinion leader call on IPH4102 “TELLOMAK” clinical trial design and rationale
Innate Pharma announces intention to conduct a registered offering in the United States
Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML
Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)
Outcome of Annual General Meeting of May 22, 2019
Innate Pharma announces publication on next generation immunotherapies targeting the adenosine pathway in “Cell Reports”
Innate Pharma First Quarter 2019 Report
Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)
Number of shares and voting rights of Innate Pharma as at April 18, 2019
